We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Then his mother, Alia Hayes, got some bad news. The manufacturer, GSK, was going to stop manufacturing the brand-name ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK said Wednesday that core operating profit increased five percent in the third quarter. "Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new ...

GSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

Haleon missed third-quarter revenue and profit expectations on Thursday, hit by a stronger pound and lower sales of its ...

Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have now built into GSK's ...

GSK is delivering consistent financial performance ... 14,000,15,000 people die every year in America. This is a brand-new vaccine with a cautious ACIP, but we are in their hands in terms of ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.